Home › Funds › Foresite Capital Management VI LLC › DNLI
Foresite Capital Management VI LLC position in DNLI
DENALI THERAPEUTICS INC · Health Care
Foresite Capital Management VI LLC reported holding 1,396,771 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$35.9M, representing 5.59% of its reported portfolio and ranking #4 among its reported holdings. Foresite Capital Management VI LLC has disclosed DNLI holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management VI LLC's DNLI position evolved
Foresite Capital Management VI LLC first disclosed a stake in DNLI in Q3 2025 at 1,000,000 shares (US$14.5M). The position peaked in Q2 2026 at 1,396,771 shares, worth US$35.9M. Across 4 filings, Foresite Capital Management VI LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,396,771 shares valued at US$35.9M — an increase of 186,800 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.00M | $14.52M | New |
| Q4 2025 | 1.00M | $16.51M | Hold |
| Q1 2026 | 1.21M | $23.23M | Add |
| Q2 2026 | 1.40M | $35.92M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $180.37M · Q2 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Siren, L.L.C. 1.40M sh · $35.92M · Q2 2026
- ADAR1 Capital Management, LLC 1.03M sh · $26.47M · Q2 2026
More on Foresite Capital Management VI LLC
FAQ
How long has Foresite Capital Management VI LLC held DNLI?
Foresite Capital Management VI LLC has disclosed DNLI holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Foresite Capital Management VI LLC's current position in DNLI?
As of Q2 2026, Foresite Capital Management VI LLC holds 1.40M shares of DNLI (DENALI THERAPEUTICS INC), valued at $35.92M, representing 5.59% of its reported portfolio and ranking #4.
Has Foresite Capital Management VI LLC been buying or selling DNLI?
In the latest 13F filing (Q2 2026), Foresite Capital Management VI LLC increased its position in DNLI. The position peaked in Q2 2026 at 1.40M shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.